Carbapenem Market Size, Share and Forecast Trends - Growth Analysis and Outlook Report 2026-2030

Carbapenems are intravenously administered antibiotics reserved for serious hospital-acquired and resistant infections, including those caused by ESBL-producing Enterobacteriaceae and other Gram-negative pathogens. The market is currently valued at about $5.22 billion in 2025 and is expected to grow at roughly 5.2% per year, supported by rising hospitalization rates and the global spread of resistant bacterial strains. Mature products such as meropenem, imipenem-cilastatin, ertapenem, and doripenem dominate sales, while generic versions continue to capture share in cost-sensitive markets.

• •Global market value: approximately $5.22 billion in 2025.
• •Forecast CAGR: around 5.2% per year over the forecast period.
• •Core products include meropenem, imipenem-cilastatin, ertapenem, and doripenem.

The most powerful growth driver is the rising prevalence of carbapenem-resistant and other multidrug-resistant infections, which increases clinical reliance on these last-line therapies. Expanding hospital infrastructure, particularly in Asia-Pacific and Latin America, is widening the patient pool eligible for carbapenem treatment. Patent expirations of leading brands have also opened the door to broader generic penetration, improving access and lifting unit volumes.

• •Rising incidence of multidrug-resistant Gram-negative infections worldwide.
• •Expansion of hospital capacity and ICU admissions in emerging markets.
• •Increased availability of generic formulations following patent expiries.

By molecule, meropenem typically represents the largest revenue segment, followed by imipenem-cilastatin and ertapenem, with doripenem and newer agents holding smaller shares. By distribution channel, hospital pharmacies dominate because carbapenems are almost exclusively administered in inpatient settings under strict stewardship. North America and Europe lead in revenue, while Asia-Pacific is the fastest-growing region due to healthcare investment, larger patient populations, and improving access to advanced antibiotics.

• •Leading molecules: meropenem and imipenem-cilastatin account for the majority of revenue.
• •Dominant channel: hospital and institutional pharmacy sales.
• •Asia-Pacific is the fastest-growing regional market; North America and Europe remain the largest by value.

What are the recent trends and outlook?

The outlook through 2030 is shaped by tighter antimicrobial stewardship programs that encourage appropriate carbapenem use rather than volume expansion, even as resistance pressures remain intense. Combination therapies pairing carbapenems with beta-lactamase inhibitors are an active area of development, aiming to restore efficacy against resistant strains. Manufacturers are also investing in manufacturing capacity and supply-chain resilience to address periodic global shortages that have affected this category in recent years.

• •Combination carbapenem-plus-inhibitor therapies are an emerging development focus.
• •Antimicrobial stewardship programs are influencing prescribing patterns.
• •Supply-chain reliability and capacity expansion remain strategic priorities for manufacturers.